The new function of 3DVH software for dose calculation inside the patient undergoing TomoTherapy treatment by applying the measured data obtained by ArcCHECK was recently released. In this study, the dosimetric accuracy of 3DVH for the TomoTherapy DQA process was evaluated by the comparison of measured dose distribution with the dose calculated using 3DVH. The 2D diode detector array MapCHECK phantom was used for the TomoTherapy planning of virtual patient and for the measurement of the compared dose. The average pass rate of gamma evaluation between the measured dose in the MapCHECK phantom and the recalculated dose in 3DVH was 92.6±3.5%, and the error was greater than the average pass rate, 99.0±1.2%, in the gamma evaluation results with the dose calculated in TomoTherapy planning system. The error was also greater than that in the gamma evaluation results in the RapidArc analysis, which showed the average pass rate of 99.3± 0.9%. The evaluated accuracy of 3DVH software for TomoTherapy DQA process in this study seemed to have some uncertainty for the clinical use. It is recommended to perform a proper analysis before using the 3DVH software for dose recalculation of the patient in the TomoTherapy DQA process considering the initial application stage in clinical use.
Introduction
Delivery quality assurance (DQA) for the verification of the dosimetric accuracy of intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) has been investigated in various studies. [1] [2] [3] A conventional basic procedure for DQA is the measurement of dose distribution in a phantom structure. The dosimetric errors are then analyzed by comparing the measured data with the calculated dose in a treatment planning system (TPS).
The conventional DQA process has some limitation as it measures and analyzes the dose in a phantom material and not within the body of the patient. 4, 5) In order to overcome this limitation, special softwares were developed for calculation of the dose distribution in the patient's body using the measured data in the DQA process. [6] [7] [8] [9] [10] [11] [12] [13] A 3DVH software (SunNuclear, The function of 3DVH for dose calculation inside the patient undergoing TomoTherapy (Accuray, Sunnyvale, CA) treat- 
Materials and Methods

Preparation of the TomoTherapy plan
The 2D diode detector array MapCHECK (SunNuclear, Mel- were prepared based on the CT images. The virtual target and organ at risk (OAR) were contoured differently in each plan (Fig. 2) , and the TomoTherpy plans were prepared according to the dose prescription, as shown in Table 1 .
Dose calculation with 3DVH
The DQA plans of the prepared TomoTherapy plans were made for the acquisition of measured dose data by using the ArcCHECK device. After the DQA measurement by using the ArcCHECK, as shown in Fig. 3 , the error compared with the calculated dose in the TomoTherapy planning system was evaluated using the gamma evaluation method with a 3% dose difference and 3-mm distance-to-agreement criteria. The measured dose data by using the ArcCHECK was imported to 
Analysis on the dosimetric accuracy of 3DVH
The dose difference between the measured and calculated dose in 3DVH was evaluated using the gamma evaluation method with a 3% dose difference and 3-mm distance-toagreement criteria.
The additional ten RapidArc plans were prepared with the same MapCHECK phantom, target, OARs and dose prescription as used in the TomoTherapy plans. The DQA plans were prepared for dose measurement by using the ArcCEHCK.
After the DQA accuracy was confirmed, the measured dose data by using the ArcCHECK was imported to 3DVH for 3D The evaluated 3DVH accuracy in the RapidArc DQA process was compared with the results in the TomoTherapy case and the suitability of the 3DVH application in the TomoTherapy DQA was examined.
Results
The calculated pass rate in the gamma evaluation of TomoTherapy DQA by using the ArcCHECK is shown in Table 2 .
The average pass rate was 98.3±1.2%, which proved to be the acceptable agreement between the calculated dose and the measured dose in TomoTherapy.
The results obtained by comparing the calculated dose at level of 2D diode detector array in the TomoTherapy planning system and the measured dose distribution in the MapCHECK phantom are shown in Table 3 . The average pass rate of the gamma evaluation was 99.0±1.2%, which was in good agreement with the calculated dose by using the TomoTherapy planning system and the measured dose.
The results of gamma evaluation between the measured dose in the MapCHECK phantom and the recalculated dose in 3DVH are shown in Table 4 . The average pass rate was 92.6±
3.5%, and the error was greater than that in the gamma evaluation results with the dose calculated in TomoTherapy planning system.
The results of gamma evaluation in the RapidArc DQA process are shown in Table 5 , Table 6 , and Table 7 . The average pass rate was 99.3±0.7% in the RapidArc DQA process using the ArcCHECK and was in good agreement. The aver- Although the evaluated inaccuracy of 3DVH in TomoTherapy might be limited to this study, it can occur in any other sites that consider insufficient application data because of the newly developed software and the lower number of TomoTherapy sites compared to the sites using a generalized LINAC based IMRT and VMAT. Therefore, it is better to perform a proper analysis before using the 3DVH software for dose recalculation of the patient in the TomoTherapy DQA process. The further study on the error analysis will be done with the additional phantom measurements data in order to find the proper method to apply the 3DVH in TomoTherapy DQA.
Conclusion
The 3DVH software for the dose recalculation inside the body of the patient in the TomoTherapy DQA process is esti-mated to have some uncertainty like the results in this study considering the initial application in clinical cases. A proper verification study on the dosimetric accuracy should be performed by comparing the recalculated dose in the 3DVH software with the measured dose before application to a real clinical case.
